These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22583155)

  • 1. Gantenerumab for the treatment of Alzheimer's disease.
    Delrieu J; Ousset PJ; Vellas B
    Expert Opin Biol Ther; 2012 Aug; 12(8):1077-86. PubMed ID: 22583155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bapineuzumab.
    Kerchner GA; Boxer AL
    Expert Opin Biol Ther; 2010 Jul; 10(7):1121-30. PubMed ID: 20497044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
    Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
    J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
    Novakovic D; Feligioni M; Scaccianoce S; Caruso A; Piccinin S; Schepisi C; Errico F; Mercuri NB; Nicoletti F; Nisticò R
    Drug Des Devel Ther; 2013; 7():1359-64. PubMed ID: 24255592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive antiamyloid immunotherapy for Alzheimer's disease.
    Loureiro JC; Pais MV; Stella F; Radanovic M; Teixeira AL; Forlenza OV; de Souza LC
    Curr Opin Psychiatry; 2020 May; 33(3):284-291. PubMed ID: 32040044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.
    Azargoonjahromi A
    J Pharm Pharmacol; 2024 Sep; 76(9):1115-1131. PubMed ID: 38767981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
    Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
    Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
    Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
    Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
    Jacobsen H; Ozmen L; Caruso A; Narquizian R; Hilpert H; Jacobsen B; Terwel D; Tanghe A; Bohrmann B
    J Neurosci; 2014 Aug; 34(35):11621-30. PubMed ID: 25164658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
    Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
    Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
    Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
    Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
    J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy for Alzheimer's disease].
    Falkentoft AC; Hasselbalch SG
    Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
    Bateman RJ; Cummings J; Schobel S; Salloway S; Vellas B; Boada M; Black SE; Blennow K; Fontoura P; Klein G; Assunção SS; Smith J; Doody RS
    Alzheimers Res Ther; 2022 Nov; 14(1):178. PubMed ID: 36447240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.